MetaCap

Geron Corporation (GERN)

NASDAQ: GERNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.8707-0.0423 (-4.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GERN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$560.94M
EPS (TTM)
-$0.08
52-week range
0.84 – 2.01
Day range
0.8615 – 0.925
Volume / Avg
13.83M / 13.05M
Beta
—

52-week range

$0.84$2.01

GERN stock today

Geron (GERN) closed at $0.8707 on Nov 20, down 4.63% (-$0.0423), versus the S&P 500's 3.70% decline. At this level, GERN sits near the bottom of its 52-week range of $0.84 to $2.01: 56.7% below the high, set on Feb 19, 2026 and 3.7% above the low. GERN is down 34.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.3%.

Geron has posted a net loss over the last twelve months (EPS of -$0.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Geron

Company profile

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Harout Semerjian
Headquarters
Foster City, CA
Employees
258
IPO year
1996
Website
geron.com

Financial highlights

Full financials

Geron reported a net loss of $83.5 million, compared with a loss of $174.6 million a year earlier. Diluted earnings per share came in at -$0.13.

Geron annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$237.00K$596.00K$1.39M
Growth——-60.23%-57.21%+450.59%
Net income$-83.50M$-174.57M$-184.13M$-141.90M$-116.11M
EPS (diluted)$-0.13$-0.27$-0.32$-0.37$-0.35

Analyst forecast

Forecast

Consensus (5 analysts)

buy

Avg. price target

$3.50+301.98%

  • Strong buy 1
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.50High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.00 vs $-0.01
Surprise
+100.00%

GERN news

All GERN news

Geron peers

Health Care sector
GERN peer companies
CompanyPrice% ChgMarket capCompare
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs GERN
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs GERN
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs GERN
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs GERN
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs GERN
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs GERN
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs GERN
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs GERN

Indexes, lists and sector

Geron stock FAQ

What is Geron's stock price today?

GERN last traded at $0.8707 as of Nov 20, 4:00 PM EST, down 4.63% on the day. Prices are delayed at least 15 minutes.

Does Geron pay a dividend?

No. Geron does not currently pay a regular cash dividend.

Who is Geron's CEO?

Mr. Harout Semerjian is the chief executive officer of Geron Corporation, which has about 258 employees.

Has GERN ever split its stock?

Yes. The most recent GERN stock split was a 1058-for-1000 split on Jul 22, 2014.

What is the GERN 52-week high?

The 52-week high for GERN is $2.01 and the 52-week low is $0.84. The stock is currently 56.7% below its high.

Compare GERN